Lovely Meds names seven dispensing pharmacies with their cities, which almost no seller does, and charges one price at every dose on both weight-loss molecules. It also carries a federal warning letter issued in September 2025 that names its own website, and its home page prints an FDA-approval claim beside compounded product cards.
What Lovely Meds charges
Semaglutide: $175/mo — the one-month plan; three months is $145 a month, six is $120, twelve is $99
Tirzepatide: $235/mo — the one-month plan; three months is $199 a month, six is $175, twelve is $150
Sermorelin: $199/mo — from, per month; this page carries no tier table, and its body copy is a GLP-1 product's
Lovely Meds also sells 3 compounds this site boards without publishing a price for them: NAD+, Glutathione and GHK-Cu.
Lovely Meds is not a paid partner; this link may earn a commission if that changes. Full disclosure.
By Nora Castellan, Standards EditorUpdated September 2026
The warning letter is this company, not a name collision
A warning letter issued in September 2025 is attached to this record on the entity itself. Its opening line names this seller's own website as the content the agency reviewed, and the recipient block carries the company's registered name, its Maryland street address and a support email at this same domain.
That is the test applied before any letter is attached here: the document has to identify the seller, not merely share a word with it.
The named clinical group and all seven named pharmacies were then queried separately against the same federal table. None of them carries a letter.
Seven pharmacies, named and located
A regulations page lists the pharmacies that fill for it by name and city: two in Florida, two in Texas, one in Arizona, one in Nevada and one in Kentucky.
That is a real disclosure. Most sellers describe a class of pharmacy, or a network, and stop there; this one gives a reader something to look up.
It also names its clinical group. What it does not give is a state list — its own sentence reads "Lovely Meds is available in many, but not all, U.S. states," with no list and no count behind it.
A sermorelin page carrying somebody else's body copy
The sermorelin nasal-spray page prints weight-loss product copy word for word, including "Targets GLP-1 and GIP pathways for appetite control" and "Includes B12 to support energy on treatment."
Sermorelin is a growth-hormone-releasing peptide. It does not act on those pathways, and the sentences describe a different product entirely.
The figure on that page is sermorelin's; the prose beside it is not. A reader who takes the description at face value will be buying on a claim that belongs to another drug.
How to read its prices, and its FDA sentence
Both weight-loss molecules cost the same at every dose, and the full plan ladder from one month to twelve is published rather than hidden behind an intake.
The lowest rungs on those ladders are twelve-month prepay rates, not a month's price. Only the one-month rung is filed here, because that is the figure a reader actually pays in a first month.
Its terms say plainly that "Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality" — while its home page prints "FDA approved for chronic weight management" beside compounded product cards. Both are quoted; neither is endorsed, and the contradiction stands unresolved.
Who it's for
Readers who want the dispensing pharmacies named and locatable.
Buyers who do not want the price to climb as the dose does.
Shoppers comparing plan ladders from one month out to twelve.
Anyone who reads a product page for its figure and ignores its prose.
Who should look elsewhere
Buyers who rule out any seller with a federal warning letter.
Readers who need the sermorelin description to describe sermorelin.
Anyone who needs to know whether their own state is served.
Shoppers who take an FDA-approval line on a home page at face value.
Strengths
Names seven dispensing pharmacies with their cities, which almost no seller here does
Charges one price at every dose on both weight-loss molecules
Publishes the full plan ladder from one month to twelve
Says in its own words that its compounded medicines are not FDA-evaluated
Trade-offs
Carries a 2025 federal warning letter naming its own website
Its sermorelin page carries a weight-loss product's body copy word for word
Its home page prints an FDA-approval claim beside compounded product cards
Admits it is available in many but not all states without saying which
FDA disclosure
Lovely Meds received an FDA warning letter issued September 2025. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
How we verified this
Read the pharmacy list on its own regulations page and recorded all seven names with their cities.
Compared the sermorelin page's body copy against its weight-loss pages and confirmed the sentences are carried over verbatim.
Declined the twelve-month prepay floors and filed the one-month rung on each ladder instead.
Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
Confirmed the warning letter from its own opening line, which names this seller's website as the content reviewed, and from a recipient block carrying the company's address and an email at this domain — then screened the clinical group and all seven pharmacies against the same table, finding nothing.
A provider to compare Lovely Meds against
Trellis Vitality
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
Are you certain the warning letter is this company?
Yes. The letter's opening line names this site's own web address as the content the agency reviewed, and its recipient block carries the company's registered name, street address and a support email at this domain.
Does the price go up as my dose goes up?
No. On both weight-loss molecules the seller charges the same at every dose, and it publishes the plan ladder from one month to twelve.
Why does the sermorelin page describe appetite control?
Because it carries a weight-loss product's copy word for word. The price on that page is sermorelin's; the description beside it belongs to a different drug.
Which states does it serve?
It will not say. Its own sentence is that it is available in many but not all states, with no list and no count.
Lovely Meds is not a paid partner; this link may earn a commission if that changes. Full disclosure.